Executive Vice President, Chief Medical Officer and Head of Research ( 6) · Elicio Therapeutics, Inc. (ELTX)

John Neylan

FY2021 is the first fiscal year CompBrief holds for John Neylan as a named executive officer of Elicio Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,232,513

Salary $468,650Stock awards $0

3rd of 3 named executive officers at Elicio Therapeutics by FY2021 total.

3 named officers on file for Elicio Therapeutics, FY2021

John Neylan’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Elicio Therapeutics’s whole pay program stands against its peers

  • Elicio Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ELTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2022 (DEF 14A).

Free

Get John Neylan’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

John Neylan compensation by year

Elicio Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Elicio Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$468,650
Bonus$0
Stock awards$0
Option awards$763,863
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$1,232,513

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Elicio Therapeutics, Inc. DEF 14A filed April 27, 2022, accession 0001601485-22-000026, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Elicio Therapeutics, Inc. filed document, accession 0001601485-22-000026. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option58,344—$7.77
Option55,427—$16.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Elicio Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Elicio Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Jay VenkatesanPresident and Chief Executive Officer and Chairman of the Board$2,539,199
Itzhak GoldbergExecutive Chairman and Chief Scientific Officer$1,247,881
John Neylan · this pageExecutive Vice President, Chief Medical Officer and Head of Research ( 6)$1,232,513

The full Elicio Therapeutics compensation record

free company brief

This page is one person within Elicio Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Elicio Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

John Neylan's compensation dossier · One-time report. No refunds.